Blood Cancer

Blood cancers involve overgrowth and malignant transformation of blood cells (red blood cells, white blood cells or platelets) within the bone marrow. Types of blood cancers include leukemia, lymphoma and myeloma. 

This overgrowth of blood cells can reduce the bone marrow's ability to produce other types of cells, including immune cells, which impacts many aspects of the body, and the abnormal cells spill out into the bloodstream. 

Researchers at TRI are investigating different types of blood cancer in an effort to develop improved treatments:  


The Blood Cancer Research group at Mater Research, led by Professor Maher Gandhi (Mater Research CEO, Director of Mater Research Institute-UQ and senior staff haematologist) is currently investigating the tumour microenvironment in lymphoma and new biomarkers for the disease. They focus on types of lymphoma including Hodgkin Lymphoma, PTLD, Diffuse Large B-cell Lymphoma, Follicular Lymphoma and virus associated lymphomas. 

Prof Gandhi is currently leading a multi-site Phase I clinical trial of cell-based immunotherapies for patients with relapsed diffuse B-cell lymphoma. Read more


The Stem Cell and Cancer Research Group at Mater Research, led by A/Prof Ingrid Winkler, are investigating the molecular mechanisms of relapse in patients with Acute Myeloid Leukaemia (AML) following chemotherapy .

UQ-Diamantina Institute researchers are investigating work closely with clinicians and have developed a program into Chronic Lymphocytic Leukaemia (CLL) – the second most common adult leukaemia. The researchers have performed sophisticated genetic profiles on CLL patient samples and have identified key players which may be involved in the progression of the disease.

Related News

Key Researchers
Andrew Perkins
Clare Gould
Joshua Tobin
Karolina Bednarska
Linda Scott
Soi Cheng Law
Colm Keane
Ingrid Winkler
Jean-Pierre Levesque
Maher Gandhi
Show More ...
Clinician-researcher focuses on patients with rare lymphoma Haematologist, Dr Colm Keane, has a clear focus on improving patient outcomes through his lymphoma research program at the Translational...Read more
TRI-based Mater researchers in partnership with The University of Queensland have developed a new cancer vaccine, which has shown promising signs in preclinical laboratory studies. Funded by grants...Read more
An arsenal of proteins used by many cell types to communicate with and control other cells could hold the answers to treating a multitude of diseases, especially cancer. The University of Queensland...Read more
A drug currently in clinical trials has the potential to improve the survival rate of Australians diagnosed with acute myeloid leukaemia, following the outcomes of preclinical research by Mater...Read more
An important collaboration between researchers from the Mater Hospital, the Translational Research Institute (TRI) and the Griffith Institute for Drug Discovery (GRIDD) has led to a significant...Read more
Reduced immune infiltration into nodes associated with poor outcomes in follicular lymphoma Research published today in the highly prestigious Journal of Clinical Oncology by Mater Research CEO and...Read more
Can a patient’s own immune cells be modified to cure a rare and deadly type of lymphoma? Professor Maher Gandhi, CEO of Mater Research and Director of Mater Research Institute-UQ, is leading a...Read more
Cutting edge DNA test for Queensland blood cancer patients Source: Lucy Stone, Brisbane Times, 3 September 2018 MAKING A POTENTIALLY LIFE-CHANGING DECISION ABOUT BLOOD CANCER TREATMENTS COULD BECOME...Read more
Improving effectiveness of chemotherapy for treating leukaemia This research aims to overcome two major problems associated with chemotherapy for leukaemia. Stem cells within the leukaemia often...Read more
Amyloidosis News features Proteomics Facility Leukaemia Foundation's Amyloidosis Autumn 2016 newsletter features an article by Dorothy Loo from the TRI Proteomics Core Facility. The article looks...Read more